Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 · New England Journal of Medicine · 2,658 citations
https://doi.org/10.1056/nejmoa1215739
B
Brian Bressler
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
446
Papers
12.1K
Citations
47
h-index
130
i10-index
Brian Bressler is an academic researcher from University of British Columbia. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Colorectal Cancer Screening and Detection. The author has an h-index of 47, co-authored 380 publications.
ORCID: 0000-0003-4740-8209Papers by this author
worksEarly combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
2015 · The Lancet · 452 citations
https://doi.org/10.1016/s0140-6736(15)00068-9
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
2021 · Journal of Crohn s and Colitis · 139 citations
https://doi.org/10.1093/ecco-jcc/jjab058
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
2019 · Clinical Gastroenterology and Hepatology · 70 citations
https://doi.org/10.1016/j.cgh.2019.02.043
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · The Lancet · 67 citations
https://doi.org/10.1016/s0140-6736(24)01927-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat